In this study, we examine this theory using data from a randomized phase II clinical study [20] to determine whether the combination of GPC3 expression in tumor and CD16 expression on NK cells in peripheral blood can be used as useful biomarkers to identify responders to codrituzumab versus placebo. The gene discussed is GPC3; the disease is neoplasm.